You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
药明生物(02269.HK)上半年纯利预增逾78%
格隆汇 08-05 16:37

格隆汇8月5日丨药明生物(02269.HK)公布,集团预期截至2019年6月30日止六个月所录得的归属于公司权益股东的利润相比于去年同期归属于公司权益股东的利润增长78%以上。

该增长主要是由于:凭藉领先的技术平台、最佳的项目交付时间及优秀的项目执行过往记录,集团赢得更高市场份额,同时集团新增综合项目数保持快速增长;集团包括双特异性抗体平台WuXiBody在内的多个拥有自主知识产权的创新技术平台在业界获得更多应用;实施集团"跟随药物分子发展阶段扩大业务"策略带动收益大幅增长;集团业务运营效率提升;及录得其他营业外收益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account